POET Technologies Moves to Next Phase of Commercialization

New Post Public Reply Private Reply Replies (0) Message Board
sevenOdouble 11072017 #11668

POET Technologies Moves to Next Phase of Commercialization Plan, Endorses Recommendations of Special Strategic Committee

TORONTO, ONTARIO and STORRS, CONNECTICUT--(Marketwired - Aug. 16, 2013) - POET Technologies Inc. (TSX VENTURETK)(OTCQXOETF) ("the Company") - developer of the proprietary planar-optoelectronic technology ("POET") platform for monolithic fabrication of integrated electronic and optical devices on a single semiconductor wafer - announced today that its Board of Directors have endorsed the next phases of the Company's commercialization plan put forward by the Special Strategic Committee (SSC) chaired by Executive Director Peter Copetti.

The multi-pronged approach is based on discussions with potential industry partners and advisers regarding the Company's two key markets consisting of the military and commercial sector that have been identified as potential early adopters of the POET platform. Currently, while POET's incorporation in military projects is proceeding well, and should provide value in several key verticals, significant value exists in adapting POET for mass production within a commercial semiconductor fab environment. The Company must rapidly move to the next phase of its commercialization plan, which includes addressing feature size and scalability requirements for commercial fabs.

The Board has therefore endorsed, and authorized the SSC to proceed on, these recommendations, including:

  • Establishing a POET Development Alliance (PDA) - The Company will be establishing relationships with one or more industrial partners looking towards jointly adapting POET to commercial scale III-V implementation. Alliance partners will provide key input including intellectual assets, technical staff, manufacturing capability, and foundry resources. In addition to optimizing device parameters and yields, a near-term goal will be to establish comprehensive design rules and a device parameter library for POET, which will proliferate licensed designs in a POET device ecosystem. 

  • Drive for Reduction of Feature Size to 100-nm Range (100NM) - The Company will re-prioritize its technical roadmap by introducing specific milestones associated with reducing feature size from the sub-micron to the 100-nm range in scale, targeting 4Q2013 for that milestone. Consequently, the milestone for full optoelectronic integration on a single die will be re-scheduled to 2Q2014. Even without this full integration milestone, the 100-nm goal anticipates the cadence of commercial III-V foundry capabilities. This roadmap will focus the Company's ODIS subsidiary on developmental work that will allow for scalable production within existing commercial fabs. 

  • Adoption of a Shareholder Rights Plan (SRP) - The Company will be structuring a special SRP to protect the potential value of the company, for all shareholders, during the period where discussions with potential partners may be taking place regarding PDA-related agreements, and as progress on the 100NM project continues.

"This move crystallizes the Company's strategy for unlocking the value of our intellectual property," said Mr. Copetti. "A development alliance with the right partners will definitely shorten time-to-market, and help evolve a design ecosystem for POET in the marketplace."

Further SSC actions will be endorsed by the Board depending on the status of the above initiatives.

Mr. Copetti added, "While the new feature-size milestone is a challenge given our commitment to projects in our delivery pipeline, I believe the POET team is more than capable of achieving this goal. There is no doubt that POET can demonstrate its n- and p-channel capability to be a viable and scalable complement to silicon CMOS."

The Company's proprietary POET platform has demonstrated monolithic fabrication of integrated circuit gallium arsenide (GaAs) based devices containing both electronic and optical elements on a single wafer.

By offering components with the potential for increased speed, density, reliability, and lower costs, POET offers the semiconductor industry the ability to push Moore's Law to the next cadence level, overcoming current silicon-based bottlenecks, and potentially changing the roadmap for a broad range of applications.

The POET platform is currently the basis for a number of key projects - including optical code division multiple access (OCDMA) devices for avionics systems, combined RF/optical phased arrays, optoelectronic directional couplers, and ultra-low-power random access memory (RAM).

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cloud Software Group Amends $2B Cash Tender Offer

Updated Category News Views 71

Cloud Software Group is stirring the pot with an amendment that'll have bondholders looking twice at their portfolios. On November 3, 2026, the company announced a tweak to its cash tender offer, bumping up the payment for its 9.00% Senior Secured Second Lien Notes due 2029. The payout now jumps from $1,017.50 to $1,022.50 for each $1,000 of principal. If you're holding...

Continue Reading
ACLM and eClinicalWorks Expand Lifestyle Medicine Reach

Updated Category News Views 92

Changing the Game with Lifestyle Medicine When it comes to healthcare, you're always going to have the skeptics grousing about the old ways. But what happens when you take an old idea and turbocharge it with modern tech? That's where the American College of Lifestyle Medicine (ACLM) and eClinicalWorks step in. They’re throwing a new wrench into the electronic health...

Continue Reading
STVN's GLP-1 Fumble Sparks Shareholder Scrutiny

Updated Category News Views 35

The Storm Hits Stevanato: GLP-1 Blues Well, ain't this a fine pickle for Stevanato Group S.p.A. (NYSE:STVN). November 3, 2026, turned into quite the ride for those holding STVN shares. A tough third-quarter report dropped like a ton of bricks, driving the shares down after they coughed up a lower outlook for GLP-1 volumes in 2027. If you've been in the game long enough,...

Continue Reading
Tamagotchi Turns 30: Roblox Event Connects Worlds

Updated Category News Views 17

A New Chapter for an Old Favorite Dust off your digital pets, folks! Tamagotchi is not just a thing of the past. It's busting out of its shell to celebrate a big 3-0 with a splash—and get this—on Roblox. Who would've thought a plastic egg with pixels would still be out there thriving in the ether of childhood nostalgia three decades later? But it is, and it’s taking...

Continue Reading
ROBOTWORLD 2026: AI Reshapes Industrial Horizons

Updated Category News Views 48

A Grand Gathering of Robotics Minds Walking into KINTEX, Seoul's suburban behemoth of an exhibition center, you'll find a buzz that rivals the excitement of a stock floor on earnings day. It's ROBOTWORLD 2026, a stage set for tech titans and ambitious startups alike, all throwing in their chips on AI and robotics. From November 4th to 7th, 402 companies hailing from 17...

Continue Reading
3M's Huge Settlement: Navigating A Looming Legal Fog

Updated Category News Views 94

The latest chapter in 3M’s legal saga reads like a courtroom drama, but this time, the company's shelling out big bucks to sidestep prolonged courtroom battles. They're committing to a $5.8 billion payout over several years, aiming to put a lid on a massive batch of PFAS-related lawsuits. It’s like they’re cleaning the spill with a velvet mop, but the trick is...

Continue Reading
DarioHealth Taps Palumbo to Drive Healthcare Evolution

Updated Category News Views 0

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Continue Reading
VAB's Pharma Ad Guide: Emerging Trends and Insights

Updated Category News Views 191

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Continue Reading
SWFI's I20 Summit Spotlights 3,000 Promising Start-Ups

Updated Category News Views 101

Spotlight on Emerging Titans: The Future 100 Watchlist The Sovereign Wealth Fund Institute is rattling the investment cages with their latest stunt, the 'Future 100 Watchlist.' Hot off the press, this list is parading nearly 3,000 start-ups that are biting at the heels of future success. It's high stakes and higher hopes between December 11-16 at Miami's I20 Summit, where...

Continue Reading
Compass Faces Securities Fraud Suit: Deadline Looms

Updated Category News Views 45

Compass's Legal Rumble: Shareholders Take Note You know there’s trouble when a firm’s every effort at glassy-eyed optimism is slapped with a lawsuit. We've seen this song and dance far too often, and now Compass, Inc. (NYSE: COMP) takes center stage. Schall, Brown & Schwartz LLP is rallying the troops for a knock-down-drag-out class action lawsuit, accusing Compass of...

Continue Reading
s of Cautious Optimism - Continue Reading" aria-label="Continue reading: Farmer Sentiment Rises, Hints of Cautious Optimism"> Continue Reading